Thallion Pharmaceuticals

Company profile

Thallion Pharmaceuticals company profile

Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology, with a current emphasis on developing a treatment for Shigatoxin-producing E. coli (STEC) bacterial infections. The Company's leading product candidate is Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections. Thallion has completed four Phase I clinical trials evaluating the safety of Shigamabs®, which demonstrated that the antibodies are safe and well tolerated when administered both individually and in combination. In February, 2010, Thallion signed a definitive development and license agreement with Laboratoire..... For more information, log in to dureach.com to view the full company profile.